This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
search
Clinical Insider

UK CRO hVIVO wins second Asia Pacific client in 2023

Posted by on 13 February 2023
Share this article

hVIVO has signed a new testing contract with an Asia-Pacific based drug maker, which it says is an indication of its growing regional client base.

The UK contract research organisation (CRO) shared minimal details of the £6.8 million contract last week, explaining it would test the unnamed client’s respiratory syncytial virus antiviral candidate using its human challenge study model.

The Phase IIa trial will take place at hVIVO’s quarantine facilities in Whitechapel in the UK starting in the first half of next year. The firm also said its dedicated recruitment arm, FluCamp, will be responsible for finding volunteers.

CEO Yamin 'Mo' Khan said the contract was a further indication of the utility of the RSV model.

“Our RSV challenge trial model is a tried and tested model that has been used to expedite the development of several RSV vaccine candidates, and we expect that at least one of the vaccines we have worked on will reach patients this year.

“This new client will benefit from our experience and expertise to impact their drug development plans,” he said.

Khan also framed the new agreement as part of the firm’s expanding Asia-Pacific (APAC) client base.

“For hVIVO, it is highly encouraging to see our global client list continue to grow and our order book further diversify with our second significant contract with an APAC client.

“One of our goals for 2023 is to attract more customers from the APAC region, and we have already seen this come to fruition with two contracts. It is a great start to the year and builds our pipeline for 2024.

Kahn added “we expect to continue this strong momentum in the APAC region, and the rest of the world, as the growing number of biopharma companies recognise the strong value of human challenge models."

Unsplash/DannyHowe

Share this article

Sign up for Clinical Insider email updates

keyboard_arrow_down